Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providers
Hematology & Oncology Physician in Boston, MA
NPI: 1134104920Primary Practice Location
MASSACHUSETTS GENERAL HOSPITAL
55 Fruit St, Boston, MA
Primary Employer
Dana-Farber Cancer Institute
dana-farber.org
HQ Phone
Get M.D.,PH.D. Daniel's Phone Numberphone_androidMobile
Get M.D.,PH.D. Daniel's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardMA State Medical License
FL State Medical License
2022
ME State Medical License
2023 - 2027
MA State Medical License
1995 - 2026
NH State Medical License
2024 - 2026
American Board of Internal Medicine
Hematology
American Board of Internal Medicine
Medical Oncology
Albert Einstein College of Medicine
einsteinmed.edu
Medical School
Until 1993
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
Fellowship • Hematology and Medical Oncology
1996 - 1999
Mass General Brigham/Massachusetts General Hospital
Residency • Internal Medicine
1993 - 1996
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 147 | 357 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 53 | 71 |
| 3 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 46 | 159 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 38 | 38 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 34 | 39 |
Authors: Richard Newcomb, Richard Stone, Andrew Brunner, Marlise Luskin, Nneka Ufere
Journal: Cancer
Publication Date: 2023-01-18
Authors: Susan O'Brien, Anjali Advani, Erik Vandendries, Barbara Sleight, Elias Jabbour, Hagop Kantarjian, Ryan Cassaday
Journal: Clin Cancer Res
Publication Date: 2021-02-18
Authors: Jan Philipp Bewersdorf, Michael Burgess, Amer Zeidan, Martin Tallman, Jeanne Palmer, Christopher Seet
Journal: Ann Hematol
Publication Date: 2022-01-04
Lead Sponsor: AbbVie
Intervention / Treatment: DRUG: IMGN632
Lead Sponsor: Dana-Farber Cancer Institute
Collaborators: AbbVie
Intervention / Treatment: DRUG: Venetoclax, DRUG: Standard Chemotherapy
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Laboratory Biomarker Analysis, DRUG: Doxorubicin, DRUG: Dexamethasone, DRUG: Cyclophosphamide, DRUG: Cytarabine, DRUG: Vincristine Sulfate, BIOLOGICAL: Rituximab, DRUG: Methotrexate, DRUG: Mercaptopurine, DRUG: Allopurinol, DRUG: Thioguanine, PROCEDURE: Bone Marrow Aspiration and Biopsy, BIOLOGICAL: Inotuzumab Ozogamicin, DRUG: Daunorubicin Hydrochloride, DRUG: Pegylated L-Asparaginase
